XNASVRCA
Market cap63mUSD
Jan 08, Last price
0.70USD
1D
-6.71%
1Q
-45.76%
IPO
-96.22%
Name
Verrica Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
12.37
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
25.33%
Rev. gr., 5y
%
Revenues
5m
-43.27%
Net income
-67m
L+142.05%
CFO
-39m
L+106.85%
Earnings
Feb 26, 2025
Profile
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 5,124 -43.27% | 9,032 -24.73% | ||||||
Cost of revenue | 21,041 | 30,328 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (15,917) | (21,296) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 3,191 | |||||||
Tax Rate | ||||||||
NOPAT | (15,917) | (24,487) | ||||||
Net income | (66,995) 142.05% | (27,678) -28.85% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 30,300 | 26,901 | ||||||
BB yield | -9.13% | -28.63% | ||||||
| Debt | ||||||||
Debt current | 1,400 | 297 | ||||||
Long-term debt | 47,446 | 2,755 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (20,701) | (31,221) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (38,577) | (18,650) | ||||||
CAPEX | (362) | (302) | ||||||
Cash from investing activities | (362) | 54,041 | ||||||
Cash from financing activities | 74,213 | (16,870) | ||||||
FCF | (12,246) | (25,976) | ||||||
| Balance | ||||||||
Cash | 69,547 | 34,273 | ||||||
Long term investments | ||||||||
Excess cash | 69,291 | 33,821 | ||||||
Stockholders' equity | (230,444) | (163,449) | ||||||
Invested Capital | 296,417 | 205,008 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 45,342 | 34,163 | ||||||
Price | 7.32 166.18% | 2.75 -69.98% | ||||||
Market cap | 331,907 253.28% | 93,949 -62.08% | ||||||
EV | 311,206 | 62,728 | ||||||
EBITDA | (15,081) | (20,578) | ||||||
EV/EBITDA | ||||||||
Interest | 3,962 | 2,172 | ||||||
Interest/NOPBT | ||||||||